CSIMarket Company Name, Ticker, Competitors, else..
 
Bright Minds Biosciences Inc   (NASDAQ: DRUG)
 
Price: $65.0000 $-0.06 -0.092%
Day's High: $65.98999786376953 Week Perf: -4.44 %
Day's Low: $ 63.19 30 Day Perf: -19 %
Volume (M): 86,706 52 Wk High: $ 123.75
Volume (M$): $ 0 52 Wk Avg: $73.75
Open: $63.98 52 Wk Low: $44.25



 Market Capitalization (Millions $) 447
 Shares Outstanding (Millions) 7
 Employees 57
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Bright Minds Biosciences Inc. is a biotechnology company that specializes in the discovery and development of novel drugs to treat various neurological and psychiatric disorders. Their research focuses on identifying and targeting specific receptors in the brain to enhance mental health and cognitive function. Bright Minds Biosciences aims to provide innovative therapeutic solutions for conditions such as depression, anxiety, schizophrenia, and Alzheimer's disease. Through a combination of cutting-edge science and advanced technologies, they are dedicated to improving the lives of individuals suffering from these disorders.


   Company Address: 19 Vestry Street NY 10013 NY
   Company Phone Number: 407-2515   Stock Exchange / Ticker: NASDAQ DRUG


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALZN      0% 
ANRO   -13.54%    
ATAI      0% 
CMND   -46.94%    
CMPS        7.48% 
INDV   -1.54%    
• View Complete Report
   



Management Announcement

Bright Minds Biosciences Seeks Redemption with $35 Million Fundraising Amidst Financial Turmoil and Competitive Pressure,

Published Mon, Nov 4 2024 7:42 PM UTC

Bright Minds Biosciences: A $35 Million Gamble Amidst Dismal Financials and Industry CompetitionIn an audacious move that has raised eyebrows among investors and market analysts alike, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) has closed a non-brokered private placement, securing $35 million by selling 1,612,902 common shares at a price of $21.70 each. The ann...
Clinical Study

BMB-201 A New Hope in Pain Management Amidst Financial Struggles

Published Wed, Oct 16 2024 2:46 PM UTC

In the fast-paced world of pharmaceutical innovation, Bright Minds Biosciences Inc. stands at a crucial juncture as it unveils promising data on its proprietary compound, BMB-201. This mixed agonist of the 5-HT2C and 5-HT2A receptors has shown remarkable similarities in efficacy to morphine within various preclinical pain models. This breakthrough may offer a new avenue for ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 7.11
PEG (TTM) -

Financial Strength Current
Quick Ratio 35.59
Working Capital Ratio 36.1
Leverage Ratio (MRQ) 0.03
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 9.26 $
Book Value 9.14 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -164,345
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.